Xiewan Chen
Overview
Explore the profile of Xiewan Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zheng L, Lin F, Cai D, Zhang L, Yin C, Qi Y, et al.
Cancer Immunol Immunother
. 2025 Mar;
74(4):128.
PMID: 40024929
Background And Objectives: Immune checkpoint inhibitors (ICIs) bring cancer patients tumor control and survival benefits, yet they also trigger immune-related adverse effects (irAEs), notably checkpoint inhibitor-related pneumonitis (CIP), affecting about...
2.
Zeng L, Zhang L, Li L, Liao X, Yin C, Zhang L, et al.
PeerJ
. 2024 Sep;
12:e18159.
PMID: 39346064
Recent breakthrough therapies have improved survival rates in non-small cell lung cancer (NSCLC), but a paradigm for prospective confirmation is still lacking. Patientdatasets were mainly downloaded from TCGA, CPTAC and...
3.
Zeng L, Zhang L, Yin C, Chen X, Chen X, Sun L, et al.
Eur J Med Res
. 2024 May;
29(1):273.
PMID: 38720348
Background: Previous studies suggested that zinc finger protein 536 (ZNF536) was abundant in the central brain and regulated neuronal differentiation. However, the role of ZNF536 in cancer has remained unclear....
4.
Zeng L, Chen X, Cui J, Zhang L, Li L, Yin C, et al.
J Thorac Dis
. 2024 Feb;
16(1):201-214.
PMID: 38410612
Background: Programmed cell death ligand 1 (PD-L1) blocking therapy has transformed the treatment of lung adenocarcinoma (LUAD), which has significantly changed the landscape of immunotherapy. We aimed to explore specific...
5.
Zeng L, Li L, Liao X, Zhang L, Yin C, Chen X, et al.
Med Oncol
. 2024 Jan;
41(2):42.
PMID: 38170412
In lung squamous cell carcinoma (LUSC), current cancer vaccines show promising effects, despite a lack of benefit for a large number of patients. We first identified the tumor antigens into...
6.
Zhao X, Li J, Zheng L, Yang Q, Chen X, Chen X, et al.
Front Mol Biosci
. 2022 Feb;
9:786864.
PMID: 35141280
The intervention timing of immune checkpoint inhibitors (ICIs) and radiotherapy fractionations are critical factors in clinical efficacy. This study aims to explore dynamic changes of the tumor immune microenvironment (TIME)...
7.
Li Y, Wang Y, Xue F, Feng X, Ba Z, Chen J, et al.
Bioact Mater
. 2021 Sep;
7:466-477.
PMID: 34466746
Small-diameter tissue-engineered vascular grafts (sdTEVGs) with hyperglycemia resistance have not been constructed. The intimal hyperplasia caused by hyperglycemia remains problem to hinder the patency of sdTEVGs. Here, inspired by bionic...
8.
Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al.
Front Immunol
. 2020 May;
11:827.
PMID: 32425950
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed great threat to human health. T cells play a critical role in...
9.
Xu Z, Yang Q, Chen X, Zheng L, Zhang L, Yu Y, et al.
Oncol Lett
. 2019 Jun;
17(6):5590-5600.
PMID: 31186781
The prognosis of non-small cell lung cancer (NSCLC) is poor, particularly for patients with metastatic disease. Numerous efforts have been made to improve the prognosis of these patients; however, only...
10.
Zheng L, Wang Y, Xu Z, Yang Q, Zhu G, Liao X, et al.
Oncologist
. 2019 May;
24(8):1031-e612.
PMID: 31040256
Lessons Learned: This single-arm, phase II study shows that concurrent EGFR-tyrosine kinase inhibitor plus thoracic radiotherapy as the first-line treatment for stage IV non-small cell lung cancer harboring EGFR active...